Pioneering biomarker technologies for Cancer therapies

Our biomarkers are used to identify the right patient, the right drug and the right dose.

Biomarker tests


magnifying

Using our biomarker tests provides more effective treatment for patients and economic savings for the healthcare system. Our colorectal cancer tests are validated using thousands of patient samples and are set to transform the current treatment pathway.

Biomarker platforms


testtubes

Our companion diagnostic biomarker platforms are used to discover biomarkers which improve both the benefit and risk profiles of pipeline drugs.

CancerNav®

A functional genome-wide screen to discover companion diagnostic biomarkers that predict efficacy.

ToxNavTM

A genome-wide screen using the principles of toxgnostics to discover biomarkers that predict drug specific side-effects.

We are looking to partner with leading drug development companies for companion diagnostic development.

Contact us

We have reached a crossroads in cancer treatment, where we can apply innovative tests on the patient’s blood and tumour tissue to select which patients need chemotherapy, what drugs will be most effective and what is a safe dose, reducing the risk of side effects. Our portfolio of biomarker tests allows us to make a step change in the treatment of early stage colorectal cancer, a disease affecting 1.2 million new patients every year, presenting a major global burden of morbidity and mortality.”

Prof. David Kerr CBE MD DSc FRCP (Glas, Lon, Edin) FRCGP FMedSci.

January 23, 2015

Oxford Cancer Biomarkers announces funding has been awarded for a pilot study of the ColoTox test

Oxford, UK, 16th January 2015 Oxford Cancer Biomarkers Ltd (OCB), the UK-based company developing tests that allow medicines to be personalised for the benefit of the cancer patient, has today announced that the Thames Valley Cancer SCN Project has awarded funding for a pilot study to measure the clinical utility of OCB’s ColoTox test for patients undergoing adjuvant treatment for colorectal... more

September 1, 2014

Oxford Cancer Biomarkers announces biomarker discovery and development deal with Daiichi-Sankyo

Oxford, UK, 29th August 2014 Oxford Cancer Biomarkers Ltd (OCB), the UK-based company developing tests that allow medicines to be personalised for the benefit of the cancer patient, has today announced an agreement with Daiichi-Sankyo for biomarker discovery, with the potential for further collaboration on validation and development of resulting biomarkers. OCB will work with a Daiichi-Sankyo... more

July 25, 2014

Oxford Cancer Biomarkers announces issued United States patent

Oxford, UK, 24 July 2014 Oxford Cancer Biomarkers Ltd (OCB), the UK-based company developing tests that allow medicines to be personalised for the benefit of the cancer patient, has today announced that the United States patent for its biomarker platform CancerNav® has been issued. CancerNav® provides a powerful approach to discovering biomarkers that have the potential to predict responding... more
doctor

Partnering with Pharmaceutical companies

We partner with leading pharmaceutical companies to develop cost effective companion biomarkers for pipeline drugs using our patented technology.

Learn more